Literature DB >> 25303718

Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition.

Maider Ibarrola-Villava1, Rajiv Kumar, Eduardo Nagore, Meriem Benfodda, Mickael Guedj, Steven Gazal, Hui-Han Hu, Jian Guan, P Sivaramakishna Rachkonda, Vincent Descamps, Nicole Basset-Seguin, Armand Bensussan, Martine Bagot, Philippe Saiag, Dirk Schadendorf, Manuel Martin-Gonzalez, Matias Mayor, Bernard Grandchamp, Gloria Ribas, Nadem Soufir.   

Abstract

Multifactorial predisposition to melanoma includes genes involved in pigmentation, immunity and DNA repair. Nonetheless, missing heritability in melanoma is still important. We studied the role of 335 candidate SNPs in melanoma susceptibility by using a dedicated chip and investigating 110 genes involved in different pathways. A discovery set was comprised of 1069 melanoma patients and 925 controls from France. Data were replicated using validation phases II (1085 cases and 801 controls from Spain) and III (1808 cases and 1894 controls from Germany and a second set of Spanish samples). In addition, an exome sequencing study was performed in three high-risk French melanoma families. Nineteen SNPs in 17 genes were initially associated with melanoma in the French population. Six SNPs were replicated in phase II, including two new SNPs in the WNT3 (rs199524) and VPS41 (rs11773094) genes. The role of VPS41 and WNT3 was confirmed in a meta-analysis (3940 melanoma cases and 3620 controls) with two-side p values of 0.002, (OR = 0.86) and 4.07 × 10(-10) (OR = 0.80), respectively. Exome sequencing revealed a non-synonymous VPS41 variant in one family that was shown to be strongly associated with familial melanoma (OR = 4.46, p = 0.001) in an independent sample of 178 melanoma families. WNT3 belongs to WNT pathway known to play a crucial role in melanoma, whereas VPS41 regulates vesicular trafficking and is thought to play a role in pigmentation. Our work identified two new pathways involved in melanoma predisposition. These results may be useful in the future for identifying individuals highly predisposed to melanoma.
© 2014 UICC.

Entities:  

Keywords:  VPS41; WNT3; case-control study; exome sequencing; melanoma

Mesh:

Substances:

Year:  2014        PMID: 25303718     DOI: 10.1002/ijc.29257

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  A polymorphic GGC repeat in the NPAS2 gene and its association with melanoma.

Authors:  Alessandra Franzoni; Elitza Markova-Car; Sanja Dević-Pavlić; Davor Jurišić; Cinzia Puppin; Catia Mio; Marila De Luca; Giulia Petruz; Giuseppe Damante; Sandra Kraljević Pavelić
Journal:  Exp Biol Med (Maywood)       Date:  2017-08-11

2.  Genetic Variants in WNT2B and BTRC Predict Melanoma Survival.

Authors:  Qiong Shi; Hongliang Liu; Peng Han; Chunying Li; Yanru Wang; Wenting Wu; Dakai Zhu; Christopher I Amos; Shenying Fang; Jeffrey E Lee; Jiali Han; Qingyi Wei
Journal:  J Invest Dermatol       Date:  2017-05-10       Impact factor: 8.551

3.  Overexpression of Rab25 promotes hepatocellular carcinoma cell proliferation and invasion.

Authors:  Donghua Geng; Wenyan Zhao; Yong Feng; Jingang Liu
Journal:  Tumour Biol       Date:  2015-12-21

4.  MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells.

Authors:  Diego Ploper; Vincent F Taelman; Lidia Robert; Brian S Perez; Björn Titz; Hsiao-Wang Chen; Thomas G Graeber; Erika von Euw; Antoni Ribas; Edward M De Robertis
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

Review 5.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

6.  Neurodegenerative VPS41 variants inhibit HOPS function and mTORC1-dependent TFEB/TFE3 regulation.

Authors:  Reini E N van der Welle; Rebekah Jobling; Christian Burns; Paolo Sanza; Jan A van der Beek; Alfonso Fasano; Lan Chen; Fried J Zwartkruis; Susan Zwakenberg; Edward F Griffin; Corlinda Ten Brink; Tineke Veenendaal; Nalan Liv; Conny M A van Ravenswaaij-Arts; Henny H Lemmink; Rolph Pfundt; Susan Blaser; Carolina Sepulveda; Andres M Lozano; Grace Yoon; Teresa Santiago-Sim; Cedric S Asensio; Guy A Caldwell; Kim A Caldwell; David Chitayat; Judith Klumperman
Journal:  EMBO Mol Med       Date:  2021-04-14       Impact factor: 12.137

7.  TbVps41 regulates trafficking of endocytic but not biosynthetic cargo to lysosomes of bloodstream forms of Trypanosoma brucei.

Authors:  Srinivasan Ramakrishnan; Rodrigo P Baptista; Beejan Asady; Guozhong Huang; Roberto Docampo
Journal:  FASEB J       Date:  2021-06       Impact factor: 5.834

8.  Sex-specific genetic effects associated with pigmentation, sensitivity to sunlight, and melanoma in a population of Spanish origin.

Authors:  Barbara Hernando; Maider Ibarrola-Villava; Lara P Fernandez; Maria Peña-Chilet; Marta Llorca-Cardeñosa; Sara S Oltra; Santos Alonso; Maria Dolores Boyano; Conrado Martinez-Cadenas; Gloria Ribas
Journal:  Biol Sex Differ       Date:  2016-03-18       Impact factor: 5.027

9.  Whole genome sequencing and 6-year follow-up of a mother and daughter with frontometaphyseal dysplasia associated with keratitis, xerosis, poikiloderma, and acro-osteolysis: A case report.

Authors:  Heng Xie; Li Xue; Wei Hua; Bangsheng Jia; Liang Zhang; Li Li
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

10.  The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.

Authors:  Gareth J Inman; Jun Wang; Ai Nagano; Ludmil B Alexandrov; Karin J Purdie; Richard G Taylor; Victoria Sherwood; Jason Thomson; Sarah Hogan; Lindsay C Spender; Andrew P South; Michael Stratton; Claude Chelala; Catherine A Harwood; Charlotte M Proby; Irene M Leigh
Journal:  Nat Commun       Date:  2018-09-10       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.